Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Melanoma research

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00008390-200304000-00013PMID 12690304
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomised phase II study of carmustine alone or in combination with tomour necrosis factor in patients with advanced melanoma

  2004cited by this paper
• Temporal changes in insulin sensitivity following the development of acute liver failure secondary to acetaminophen

  2001cited by this paper
• Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).

  1999cited by this paper
• Co-regulation of melanin precursors and tyrosinase in human pigment cells: roles of cysteine and glutathione.

  1999cited by this paper
• Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.

  1999cited by this paper
• Carbamoylation of glutathione reductase by N,N-bis(2-chloroethyl)-N- nitrosourea associated with inhibition of multidrug resistance protein (MRP) function.

  1997cited by this paper
• Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture.

  1997cited by this paper
• Validated high-performance liquid chromatography-electrochemical method for determination of glutathione and glutathione disulfide in small tissue samples.

  1997cited by this paper
• Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue.

  1996cited by this paper
• Ethacrynic acid: a novel radiation enhancer in human carcinoma cells.

  1996cited by this paper
• Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.

  1996cited by this paper
• Use of lymphocytes for assessing ethanol-mediated alterations in the expression of hepatic cytochrome P4502E1.

  1995cited by this paper
• Susceptibility of human melanoma cells to oxidative stress including UVA radiation.

  1995cited by this paper
• Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

  1994cited by this paper
• Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.

  1994cited by this paper
• Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis

  1993cited by this paper
• Chemotherapy of metastatic melanoma.

  1992cited by this paper
• Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells

  1992cited by this paper
• Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.

  1992cited by this paper
• Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells

  1992cited by this paper
• Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma.

  1991cited by this paper
• Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.

  1989cited by this paper
• Characterization of the inhibition of glutathione reductase and the recovery of enzyme activity in exponentially growing murine leukemia (L1210) cells treated with 1,3-bis(2-chloroethyl)-1-nitrosourea.

  1988cited by this paper
• Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation.

  1985cited by this paper
• Modification of chemotherapy by nitroimidazoles.

  1984cited by this paper
• Inhibition of glutathione synthesis augments lysis of murine tumor cells by sulfhydryl-reactive antineoplastics.

  1983cited by this paper
• Chemotherapy of malignant melanoma

  1979cited by this paper
• Chemotherapy of malignant melanoma

  1972cited by this paper

• High dose acetaminophen re-polarizes CD11b+ cells in the tumor microenvironment towards an activated macrophage phenotype

  2025cites this paper
• Modeling and Simulation of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended‐Release and Immediate‐Release Formulations in Healthy Adults Using the Quantitative Systems Toxicology Software Platform DILIsym

  2025cites this paper
• High-Dose Acetaminophen as a Treatment for Cancer

  2024cites this paper
• Small-molecule redox modulators with anticancer activity: A comprehensive mechanistic update.

  2023cites this paper
• Population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations

  2022cites this paper
• Optimal biological dose: a systematic review in cancer phase I clinical trials

  2021cites this paper
• Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma

  2020cites this paper
• The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood–Brain Barrier in Rats

  2020cites this paper
• The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: An evidence-based view.

  2017cites this paper
• Can a serum acetaminophen concentration obtained less than 4 hours post-ingestion determine which patients do not require treatment with acetylcysteine?*

  2017cites this paper
• Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy

  2016cites this paper
• Intractable Disease in the Elderly : When Conventional Therapy Fails

  2016cites this paper
• The HK2 Dependent “Warburg Effect” and Mitochondrial Oxidative Phosphorylation in Cancer: Targets for Effective Therapy with 3-Bromopyruvate

  2016cites this paper
• A novel approach for estimating ingested dose associated with paracetamol overdose.

  2016cites this paper
• Computational modeling of the pharmacokinetics and pharmacodynamics of selected xenobiotics

  2016cites this paper
• Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma

  2016cites this paper
• Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants

  2015cites this paper
• Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study

  2014cites this paper
• Preclinical high‐dose acetaminophen with N‐acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors

  2014cites this paper
• The formulation for cancer prevention & therapy

  2013cites this paper
• Determination of glutathione in individual Ramos cells by capillary electrophoresis with electrochemiluminescence detection

  2013cites this paper
• The Role of Chemotherapy for Metastatic Disease

  2013cites this paper
• Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma.

  2013cites this paper
• Chemoprevention of melanoma Chemopreventive drugs and their pharmacological mechanism of action , efficacy , safety and tolerability

  2010cites this paper
• Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice.

  2009cites this paper
• Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1.

  2009cites this paper
• Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines.

  2009cites this paper
• The protective effects of garlic extract against acetaminophen-induced oxidative stress and glutathione depletion.

  2009cites this paper
• Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities

  2009cites this paper
• Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines.

  2009cites this paper
• Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines

  2008cites this paper
• The potential utility of acetaminophen in the treatment of cell-mediated autoimmune disorders.

  2008cites this paper
• Acetaminophen Overdose with Altered Acetaminophen Pharmacokinetics and Hepatotoxicity Associated with Premature Cessation of Intravenous N-Acetylcysteine Therapy

  2008cites this paper
• Integrative Medicine and Cancer: Treatment Strategies

  2007cites this paper
• High-Dose Acetaminophen Inhibits the Lethal Effect of Doxorubicin in HepG2 Cells: The Role of P-glycoprotein and Mitogen-Activated Protein Kinase p44/42 Pathway

  2007cites this paper
• Involvement of the multidrug resistance P-glycoprotein in acetaminophen-induced toxicity in hepatoma-derived HepG2 and Hep3B cells.

  2006cites this paper
• Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith–Wiedemann syndrome with high dose acetaminophen and N‐acetylcysteine rescue

  2005cites this paper
• The current role of systemic therapy in the management of Malignant Melanoma of the skin: a literature review

  2004cites this paper
• Glutathione is involved in the antimalarial action of chloroquine and its modulation affects drug sensitivity of human and murine species of Plasmodium

  2003cites this paper
• Potentiation of the antimalarial action of chloroquine in rodent malaria by drugs known to reduce cellular glutathione levels.

  2003cites this paper
• Drug Resistance in Human Melanoma: Mechanisms and Therapeutic Opportunities

  2003cites this paper
• DNA-binding agents.

  2002cites this paper